We are live on
!
Find out more
QC
Quantessence Capital Portfolio holdings
AUM
$20.5M
1-Year Est. Return
71.02%
This Fund
S&P 500
This Quarter
Est. Return
+14.43%
1 Year Est. Return
+71.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$60.2M
(-15%)
Cap. Flow
-$87.3M
Cap. Flow
% of AUM
-25.71%
Top 10 Holdings %
Top 10 Hldgs %
46.41%
Holding
483
New
151
Increased
11
Reduced
18
Closed
302
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AZEK
The AZEK Co
AZEK
|
+$58.6M |
| 2 |
RDFN
Redfin
RDFN
|
+$35.6M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$8.53M |
| 4 |
Sprouts Farmers Market
SFM
|
+$7.45M |
| 5 |
Insmed
INSM
|
+$5.79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$30.3M |
| 2 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$12.3M |
| 3 |
ExxonMobil
XOM
|
+$11.3M |
| 4 |
BECN
Beacon Roofing Supply, Inc.
BECN
|
+$10.8M |
| 5 |
Pfizer
PFE
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 31.47% |
| 2 | Real Estate | 13.23% |
| 3 | Healthcare | 10.04% |
| 4 | Financials | 9.26% |
| 5 | Consumer Discretionary | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBGS
151
JBG SMITH
JBGS
$865M
| $256K | 0.08% |
+14,780
| New | +$241K |
|
152
Opendoor
OPEN
$4.32B
| $255K | 0.08% |
+495,195
| New | +$358K |
|
153
Henry Schein
HSIC
$10B
| $252K | 0.07% |
3,455
-21,844
| -86% | -$1.5M |
|
154
AeroVironment
AVAV
$7.17B
| $237K | 0.07% |
+833
| New | +$141K |
|
155
FTI Consulting
FCN
$4.85B
| $235K | 0.07% |
1,457
-943
| -39% | -$154K |
|
156
Huntington Ingalls Industries
HII
$10.7B
| $235K | 0.07% |
+974
| New | +$218K |
|
157
Lincoln Electric
LECO
$13.9B
| $227K | 0.07% |
+1,094
| New | +$209K |
|
158
Nektar Therapeutics
NKTR
$2.31B
| $223K | 0.07% |
+8,645
| New | +$97.1K |
|
159
Leidos
LDOS
$13.4B
| $222K | 0.07% |
+1,408
| New | +$208K |
|
160
Hilton Grand Vacations
HGV
$3.93B
| $218K | 0.06% |
+5,244
| New | +$198K |
|
161
ChargePoint
CHPT
$149M
| $211K | 0.06% |
+15,018
| New | +$201K |
|
162
Generac Holdings
GNRC
$12.8B
| $205K | 0.06% |
+1,433
| New | +$175K |
|
163
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
| $204K | 0.06% |
+1,517
| New | +$205K |
|
164
BlackLine
BL
$1.73B
| $200K | 0.06% |
+3,533
| New | +$182K |
|
165
Ocugen
OCGN
$464M
| $195K | 0.06% |
+200,783
| New | +$167K |
|
166
Lumen
LUMN
$6.53B
| $194K | 0.06% |
+44,178
| New | +$171K |
|
167
FIGS
FIGS
$1.72B
| $184K | 0.05% |
+32,640
| New | +$151K |
|
|
DVAX
168
DELISTED
Dynavax Technologies
DVAX
| $180K | 0.05% |
+18,186
| New | +$192K |
|
|
IAUX
169
i-80 Gold Corp
IAUX
$1.11B
| $135K | 0.04% |
+225,991
| New | +$133K |
|
170
Oric Pharmaceuticals
ORIC
$1.14B
| $120K | 0.04% |
+11,868
| New | +$79.7K |
|
171
American Express Global Business Travel
GBTG
$4.91B
| $120K | 0.04% |
+18,985
| New | +$122K |
|
172
Ocular Therapeutix
OCUL
$1.98B
| $106K | 0.03% |
+11,467
| New | +$89.8K |
|
173
Aurinia Pharmaceuticals
AUPH
$2.06B
| $100K | 0.03% |
+11,822
| New | +$94.8K |
|
|
GOGL
174
DELISTED
Golden Ocean Group
GOGL
| $94.9K | 0.03% |
+12,969
| New | +$98.3K |
|
175
SES AI
SES
$237M
| $90.8K | 0.03% |
+102,207
| New | +$85.8K |
|
Similar funds
FS
HIIL
BC
PMAM
LFA
HAM
DP
SPC
Quantessence Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Quantessence Capital held 483 positions worth $340M, down 15% from $400M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Quantessence Capital withdrew a net $87.3M in Q2 2025, closing 302 positions and reducing 18 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $30.3M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 31% of assets, up from 11% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Quantessence Capital opened a new position in The AZEK Co worth $63.6M.
- Quantessence Capital's largest Q2 2025 buy was The AZEK Co: 1,170,131 shares worth $63.6M.
- Quantessence Capital added most to Merck in Q2 2025, an estimated $3.19M increase.
- Quantessence Capital's biggest Q2 2025 reduction was State Street Financial Select Sector SPDR ETF, cutting an estimated $1.84M.
- Quantessence Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $30.3M.
- Quantessence Capital's ten largest holdings make up 46% of its $340M portfolio in Q2 2025.
- Quantessence Capital opened 151 new positions and closed 302 in Q2 2025.
- Quantessence Capital's portfolio value fell 15% quarter-over-quarter to $340M.
Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.